Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system

Benzer Materyaller

• Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system
  Yazar:: Xiuping Feng, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-06-01)
• Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system
  Yazar:: Lingti Kong, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-05-01)
• Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
  Yazar:: Xiaoxuan Xing, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-01-01)
• A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
  Yazar:: Zhong Xue, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-11-01)
• Disproportionality analysis of satralizumab in FDA adverse event reporting system and Japanese adverse drug event report: a pharmacovigilance study
  Yazar:: Linhai Zhang, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-01-01)